|
1
|
Lim YS, Lampertico P. Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? Authors' reply. Aliment Pharmacol Ther 2022; 55:1044-1045. [PMID: 35362138 DOI: 10.1111/apt.16886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
LINKED CONTENTThis article is linked to Lim et al papers. To view these articles, visit https://doi.org/10.1111/apt.16788 and https://doi.org/10.1111/apt.16854
Collapse
Affiliation(s)
- Young-Suk Lim
- Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Pietro Lampertico
- Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy
- CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| |
Collapse
|